With a strong finish in the second half of 2013, the Dutch, private biotechnology companies closed the year having amassed a total of USD 158m in venture financing. The strongest therapeutic areas, as represented by the biotech product pipeline (Therapeutics and Diagnostics), are those of Oncology (53 products in development), Infectious Diseases (36 products) and Diseases of the Nervous System (30 products).
Click here to download Dutch Life Sciences Trend Analysis 2014 – 14 pages
Looking for your next Biotech or Medtech partner?
Use Biotechgate to identify new leads, licensing opportunities and management details.